Utility weights for allergic rhinitis based on a community surgery with a time trade-off technique in Japan

Allergology International

Volumn 58, Issue 2, 2009, Pages 201-207

  Tamayama, Kazuhiro ^a,b   Kondo, Masahide ^a   Shono, Aiko ^a   Okubo, Ichiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Yokohama Stroke and Brain Center   (Japan)

Author keywords

Pollinosis; Quality of life; Quality adjusted life years; Seasonal allergic rhinitis; Utility theory

Indexed keywords

ADULT; AGE; ALLERGIC RHINITIS; ANALYTIC METHOD; ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HEALTH STATUS; HEALTH SURVEY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLLEN ALLERGY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RATING SCALE; RELIABILITY; SEX DIFFERENCE; SYMPTOM; TIME TRADE OFF TECHNIQUE; UTILITY WEIGHT;

ADULT; AGE FACTORS; AGED; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; JAPAN; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; SEX FACTORS; YOUNG ADULT;

EID: 67651162310     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.08-OA-0032     Document Type: Article

References (34)

1. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62(Suppl 85):17-25.
2. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy 2007;62 (Suppl 85):9-16.
3. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64.
4. Meltzer EO, Szwarcberg J, Pill MW. Allergic rhinitis, asthma, and rhinosinusitis: diseases of the integrated airway. J Manag Care Pharm 2004;10:310-7.
5. Okuda M. Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 2003;91: 288-96.
6. PG-MARJ Committee. [Practical Guideline for the Management of Allergic Rhinitis in Japan], 5th edn. Tokyo: Life Science, 2005 (in Japanese).
7. Okuda M, Ohkubo K, Goto M et al. Comparative study of two Japanese rhinoconjunctivitis quality-of-life questionnaires. Acta Otolaryngol 2005;125:736-44.
8. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
9. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16:199-208.
10. Monden A, Ogino S. [The evaluation of the utility values for allergic rhinitis patients using EQ-5D]. [Journal of Japan Society of Immunology and Allergology in Otolaryngology] 2005;23:15-8 (in Japanese).
11. Kawaguchi T, Hoshiyama Y, Watanabe Y. [Cost of ceder pollinosis]. Arerugi no Rinsho 2001;22:178-82 (in Japanese).
12. Okuda M. Arerugisei bien no chiryo ni ikurakakaruka. i Allergology & Immunology] 1998;5:615-20 (in Japanese).
13. Scadding GK, Bousquet J. Introduction: allergic rhinitis. Allergy 2007;62 (Suppl 85):3-5.
14. Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 2004;20:305-17.
15. Fox-Rushby J, Carins J. Economic Evaluation. Berkshire: Open University Press, 2005.
16. McPake B, Kumaranayake L, Normand C. Health Economics: An International Perspective. London: Routledge, 2002.
17. Buckingham K. A note on HYE (healthy years equivalent). J Health Econ 1993;12:301-9.
18. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press, 2004.
19. Keeny R, Raiffa H. Decisions with Multiple Objectives: Preference and Value Tradeoffs, 2nd edn. Cambridge: Cambridge University Press, 1993.
20. von Neumann J, Morgenstern O. Theory of Games and Economic Behavior. Princeton: Princeton University Press, 1944.
21. Brazier J, Ratcliffe J, Salomon JA, Tsuchiya A. Measuring and Valuing Health Benefits for Economic Evaluation. Oxford: Oxford University Press, 2007.
22. Stavem K. Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 1999;8:45-54.
23. Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Review of Pharmacoeconomics and Outcomes Research 2002; 2:99-108.
24. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Plann Sci 1976;10:129-36.
25. Buckingham JK, Birdsall J, Douglas JG. Comparing three versions of the time tradeoff: time for a change? Med Decis Making 1996; 16:335-47.
26. Konno A, Numata T, Nagata H, Terada N. Tsuunensei arerugi no gappei ga sugikafunsho hassho ni ataeru eikyo. Arerugi no Rinsho 1998; 18:178-81 (in Japanese).
27. Inaba A. Problems relating to declining response rates to social survey research in Japan: trends after 2000. International Journal of Japanese Sociology 2007;16:10-22.
28. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998;36:778-92.
29. Sullivan PW, Nichol MB. The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines. Value Health 2004;7:402-12.
30. Sullivan PW, Follin SL, Nichol MB. Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis. Med Care 2003;41: 1382-95.
31. Poulsen PB, Pedersen KM, Christensen J, Vestenbaek U. Economic evaluation of a tablet-based vaccination against hay fever in Denmark. Ugeskr Laeger 2008;170:138-42.
32. Canonica GW, Poulsen PB, Vestenbaek U. Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respir Med 2007;101:1885-94.
33. Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. Clin Exp Allergy 2007;37:772-9.
34. Arnesen T, Trommald M. Are QALYs based on time trade-off comparable? - A systematic review of TTO methodologies. Health Econ 2005; 14:39-53.